Status report
Get it in writing
The official USPTO status record for RYZELBRI, serial 88578951, as a dated PDF. One price, one document, delivered in about a minute.
INSTANT DELIVERY
Trademark Status Report
$7.99
The USPTO's own status record for this mark, on one dated page.
- Current status with a plain-English verdict
- Owner, classes, filing basis, and every key date
- The mark as it appears on the federal record
- Every prosecution event, filing to today
- Source-cited with the exact retrieval date
Built from the USPTO's TSDR record. Assignment chain of title and TTAB proceeding files sit in separate USPTO systems and are not included.
Preview
◆ TRADEMARKCHECKER.AITRADEMARK STATUS REPORT
RYZELBRISerial 88578951 · Principal Register
Dead · Refused
Owner: Ovid Therapeutics Inc.
Class 005 - Pharmaceuticals
Filed Aug 14, 2019
The record shows that the application for RYZELBRI (Serial 88578951) was abandoned on June 2, 2020, after the applicant, Ovid Therapeutics Inc., failed to respond to an Office action, so the mark is not live or registered. The only goods listed are “pharmaceutical preparations for the treatment of developmental disorders; pharmaceutical preparations for the treatment of neurological disorders” in International Class 005, meaning a similar name would raise the closest concern in the pharmaceutical field, especially for products treating those conditions. The record does not give Ovid Therapeutics control over every use of the word “RYZELBRI” in unrelated industries or contexts. Because the application was on the Principal Register and never moved to the Supplemental Register, there is no supplemental‑register sequence to note. The latest meaningful event is the abandonment notice on the same June 2, 2020 date, and no enforcement actions appear in the history. I'd treat this as a moderate concern if you plan a pharma‑related name in the same therapeutic area.
Full event history, owner details, and verdict inside.
The way I'd use it, honestly, is as the thing you attach when a bank, a marketplace, or a co-founder asks "are we clear on the name". It answers in one page.